Schnittman SM, Greenhouse JJ, Psellidopoulos MC.
et al. Increasing viral burden in CD4+ T-cells from patients with
human immunodeficiency virus (HIV) infection reflects rapidly progressive
immunosuppression and clinical disease. Ann Intern Med.1990;113:438-443.
Escaich S, Ritter J, Rougier P.
et al. Relevance of the quantitative detection of HIV proviral sequences in
PBMC of infected individuals. AIDS Res Hum Retroviruses.1992;8:1833-1837.
Yerly S, Chamot E, Hirschel B, Perrin LH. Quantitation of human immunodeficiency provirus and circulating virus:
relationship with immunologic parameters. J Infect Dis.1992;166:269-276.
Connor RI, Mohri H, Cao Y.
et al. Increased viral burden and cytopathicity correlate temporally with
CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency
virus type 1-infected individuals. J Virol.1993;67:1772-1777.
Farzadegan H, Levy D, Astemborski J, Saah AJ, Vlahov D, Graham NMH. The effect of gender, race, injecting drug use, and disease stage on
infectious HIV-1 viral burden among IDUs and gay men. In: Program and abstracts of the XI International Conference on AIDS;
July 7-12, 1996; Vancouver, British Columbia. Abstract We.C.3418.
Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency
virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol.1994;32:292-300.
Saksela K, Stevens C, Rubenstein P, Baltimore D. Human immunodeficiency virus type 1 mRNA expression in peripheral blood
cells predicts disease progression independently of the number of CD4+ lymphocytes. Proc Natl Acad Sci U S A.1994;91:1104-1108.
Holodniy M, Katzenstein D, Winters M.
et al. Measurement of HIV virus load and genotypic resistance by gene amplification
in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr.1993;6:366-369.
Mellors J, Kingsley LA, Rinaldo Jr CR.
et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med.1995;122:573-579.
Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in
Mellors JW, Muñoz A, Giorgi JV.
et al. Plasma viral load and CD4+ lymphocytes as prognostic markers
of HIV-1 infection. Ann Intern Med.1997;126:946-954.
O'Brien WA, Hartigan PM, Martin D.
et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and
the risk of progression to AIDS. N Engl J Med.1996;334:426-431.
Katzenstein DA, Hammer SM, Hughes MD.
et al. The relation of virologic and immunologic markers to clinical outcomes
after nucleoside analogue therapy in HIV-infected adults with 200 to 500 CD4
cells per cubic millimeter: AIDS Clinical Trials Group Study 175 Virologic
Study. N Engl J Med.1996;335:1091-1098.
O'Brien TR, Blattner WA, Waters D.
et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter
Hemophilia Cohort Study. JAMA.1996;276:105-110.
Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep.1989;38 Suppl 5:1-9.
Volberding PA, Lagakos SW, Koch MA.
et al. Zidovudine in asymptomatic human immunodeficiency virus infection:
a controlled trial in persons with fewer than 500 CD4-positive cells per cubic
millimeter. N Engl J Med.1990;322:941-949.
Vlahov D, Anthony JC, Muñoz A.
et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous
drug users: description of methods and characteristics of participants. NIDA Res Monogr.1991;109:75-100.
Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41:1-19.
Hoffman RA, Kunge PC, Hansen WP.
et al. Simple and rapid measurement of human T-lymphocytes and their subclasses
in peripheral blood. Proc Natl Acad Sci U S A.1980;77:4914-4917.
Giorgi JV, Cheng HL, Margolick JB.
et al. Quality control in the flow cytometric measurement of T-lymphocyte
subsets: the Multicenter AIDS Cohort experience. Clin Immunol Immunopathol.1990;55:173-186.
Manoff SB, Vlahov D, Herskowitz A.
et al. Human immunodeficiency virus infection and infective endocarditis among
injecting drug users. Epidemiology.1996;7:566-570.
Caiaffa WT, Vlahov D, Graham NMH.
et al. Drug smoking, Pneumocystis carinii pneumonia
and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency
virus-seropositive injection drug users. Am J Respir Crit Care Med.1994;150:1493-1498.
Cox DR, Oakes O. Analysis of Survival Data . London, England: Chapman & Hall; 1984.
Chaisson RE, Fuchs E, Stanton D.
et al. Racial heterogeneity of HIV antigenemia in persons with HIV infection. AIDS.1991;5:177-180.
Fahey JL, Taylor JMG, Detels R.
et al. The prognostic value of cellular and serologic markers in infection
with human immunodeficiency virus, type 1. N Engl J Med.1990;322:166-172.
Muñoz A, Vlahov D, Solomon L.
et al. Prognostic indicators for development of AIDS among intravenous drug
users. J Acquir Immune Defic Syndr.1992;5:694-700.
Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection
drug users. J Drug Issues.1995;25:225-233.
Hoover DR. The effects of long-term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. Drugs.1995;49:20-36.
Holodniy M, Mole L, Yen-Lieberman B.
et al. Comparative stabilities of quantitative human immunodeficiency virus
RNA in plasma from samples collected in vacutainer CPT, vacutainer PPT, and
standard vacutainer tubes. J Clin Microbiol.1995;33:1562-1566.
Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention
of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol.1995;10:386-390.